A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology

Volumn 138, Issue 3, 2015, Pages 507-512

  Bender, David ^a   Sill, Michael W ^b   Lankes, Heather A ^b   Reyes, Henry D ^a   Darus, Christopher J ^c   Delmore, James E ^d   Rotmensch, Jacob ^e   Gray, Heidi J ^f   Mannel, Robert S ^g   Schilder, Jeanne M ^h   Hunter, Mark I ⁱ   McCourt, Carolyn K ^j   Samuelson, Megan I ^a   Leslie, Kimberly K ^a  

^a UNIVERSITY OF IOWA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c MAINE MEDICAL CENTER   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^h INDIANA UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF MISSOURI   (United States)

^j WOMEN AND INFANTS HOSPITAL   (United States)

more..

Author keywords

Angiogenesis; Fibroblast growth factor receptor; Platelet derived growth factor receptor; Targeted therapy; Tyrosine kinase inhibitor; Vascular endothelial growth factor receptor

Indexed keywords

CEDIRANIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CAPILLARY DENSITY; CONFERENCE PAPER; CONNECTIVE TISSUE DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ENDOCRINE DISEASE; ENDOMETRIUM CANCER; EVENT FREE SURVIVAL; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; INFECTION; INJURY; INNER EAR DISEASE; KIDNEY DISEASE; LEUKOPENIA; MAJOR CLINICAL STUDY; MENTAL DISEASE; METABOLIC DISORDER; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PERIPHERAL SENSORY NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY TRACT DISEASE; SENSORY NEUROPATHY; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR DISEASE; VOMITING; ADULT; CLINICAL TRIAL; ENDOMETRIAL NEOPLASMS; MIDDLE AGED; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84941416946     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.07.018     Document Type: Conference Paper

References (28)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J. Clin. 63 2013 11 30
2. Cancer Facts and Figures 2011 American Cancer Society
3. N. Howlader, A.M. Noone, M. Krapcho, and et al. SEER Cancer Statistics Review 2013 1975 2010
4. D.S. Miller, V. Filiaci, G. Fleming, R. Mannel, D. Cohn, T. Matsumoto, and et al. Abstract: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study Gynecol. Oncol. 125 2012 771 773
5. C. Aghajanian, M.W. Sill, K.M. Darcy, B. Greer, D.S. McMeekin, P.G. Rose, and et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study J. Clin. Oncol. 29 2011 2259 2265
6. E.A. Alvarez, W.E. Brady, J.L. Walker, J. Rotmensch, X.C. Zhou, J.E. Kendrick, and et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study Gynecol. Oncol. 129 2013 22 27
7. J. Drevs, P. Siegert, M. Medinger, K. Mross, R. Strecker, U. Zirrgiebel, and et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors J. Clin. Oncol. 25 2007 3045 3054
8. T.T. Batchelor, A.G. Sorensen, E. di Tomaso, W.T. Zhang, D.G. Duda, K.S. Cohen, and et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 2007 83 95
9. U.A. Matulonis, S. Berlin, P. Ivy, K. Tyburski, C. Krasner, C. Zarwan, and et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer J. Clin. Oncol. 27 2009 5601 5606
10. F.A. Raja, C.L. Griffin, W. Qian, H. Hirte, M.K. Parmar, A.M. Swart, and et al. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer Br. J. Cancer 105 2011 884 889
11. J.A. Ledermann, T. Perren, F.A. Raja, and et al. Abstract: randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial Presented at the 2013 NCRI Cancer Conference 2013 (Liverpool, UK)
12. P. Symonds, C. Gourley, S. Davidson, and et al. CIRCCa: a randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer Presented at the ESMO 2014 Congress 2014 (Madrid, Spain)
13. Atlas of Stains: A Better Path for Cancer Diagnostics 4th ed. 2012 DAKO (http://www.dako.com/us/00230-atlas-of-stains.pdf (accessed 6 July 2015))
14. N.J. Nadkarni, K.D. Geest, T. Neff, B.D. Young, D.P. Bender, A. Ahmed, and et al. Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer Cancer Lett. 331 2013 99 104
15. M.W. Sill, L. Rubinstein, S. Litwin, and G. Yothers A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage phase II clinical trials Clin. Trials 9 2012 385 395
16. C. Spearman The proof and measurement of association between two things Am. J. Psychol. 15 1904 72 101
17. D.R. Cox Regression models and life tables J. R. Stat. Soc. Ser. B 34 1972 (187-22)
18. K.K. Leslie, M.W. Sill, H.A. Lankes, and et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer Gynecol. Oncol. 127 2012 345 350
19. K.K. Leslie, M.W. Sill, E. Fischer, K.M. Darcy, R.S. Mannel, K.S. Tewari, and et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study Gynecol. Oncol. 129 2013 486 494
20. R.L. Coleman, M.W. Sill, H.A. Lankes, A.N. Fader, N.J. Finkler, J.S. Hoffman, and et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study Gynecol. Oncol. 127 2012 538 543
21. A.M. Oza, L. Elit, M.S. Tsao, S. Kamel-Reid, J. Giagi, D.M. Provencher, and et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group J. Clin. Oncol. 29 2011 3278 3285
22. S.R. Wedge, J. Kendrew, L.F. Hennequin, P.J. Valentine, S.T. Barry, S.R. Brave, and et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer Cancer Res. 65 2005 4389 4400
23. S.A. Laurie, I. Gauthier, A. Arnold, F.A. Shepherd, P.M. Ellis, E. Chen, and et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group J. Clin. Oncol. 26 2008 1871 1878
24. J.W. Roh, J. Huang, W. Hu, X. Yang, N.B. Jennings, V. Sehgal, and et al. Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer Clin. Cancer Res. 15 2014 2740 2750
25. P.S. Lee, and A.A. Secord Targeting molecular pathways in endometrial cancer: a focus on the FGFR pathway Cancer Treat. Rev. 40 2014 507 512
26. K. Zhang, and D.J. Waxman Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model Mol. Cancer Ther. 12 2013 787 798
27. E.S. Han, R.A. Burger, K.M. Darcy, M.W. Sill, L.M. Randall, D. Chase, and et al. Predictive and prognostic angiogenic markers in gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer Gynecol. Oncol. 119 2010 484 490
28. L.M. Randall, B.J. Monk, K.M. Darcy, C. Tian, R.A. Burger, S.Y. Liao, and et al. Markers of angiogenesis in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study Gynecol. Oncol. 112 2009 583 589